The solution models of cyclo(87-99) MBP 87-99 , cyclo(87-99) [Ala 91,96 ] MBP 87-99 , and cyclo(87-99) [Arg 91 , Ala 96 ] MBP [87][88][89][90][91][92][93][94][95][96][97][98][99] have been determined through 2D NMR spectroscopy in DMSO-d 6 . Chemical shift analysis has been performed in an attempt to elucidate structural changes occurring upon substitution of native residues. NMR-derived geometrical constraints have been used in order to calculate high-resolution conformers of the above peptides. Conformational analysis of the three synthetic analogues show that the bioactivity, or the lack of it, may possibly be due to the distinct local structure observed and the subsequent differences in the overall topology and exposed area after binding with Major Histocompatibility Complex II (MHC II). It is believed that an overall larger solvent accessible area blocks the approach and binding of the T-cell receptor (TCR) on the altered peptide ligand (APL)-MHC complex, whereas more compact structures do not occlude weak interactions with an approaching TCR and can cause Experimental Autoimmune Encephalomyelitis (EAE) antagonism. A pharmacophore model based on the structural data has been generated.
Introduction
Multiple Sclerosis (MS) a is a progressive demyelinating disease of the Central Nervous System (CNS) in which a coordinated attack of the immune system takes place against the myelin sheath. 1 Although the antigenic components of Myelin in MS have not been identified with certainty yet, myelin Basic Protein (MBP) is believed to be one of the main candidate autoantigens, and MBP 87-99 is encephalitogenic in EAE, the best studied animal model for MS. [2] [3] [4] [5] [6] Analogues of immunodominant epitopes of these proteins (Altered Peptide Ligands, APLs) can induce or suppress EAE in rodents through the formation of a trimolecular complex between the MHC-peptide (antigen)-TCR and the triggering of different immunological responses. Antagonism requires an APL to induce biochemical activity, which is inhibitory over the agonist-delivered signals.
A two-step mechanism for TCR recognition has been proposed. 7 Initial TCR-MHC interactions guide the TCR to its ligand in an orientation that positions the rigid CDR1 and CDR2 loops mainly over the MHC. This is followed by a final folding of the two highly flexible CDR3 loops 8 of the TCR over the peptide. T-cell activation is triggered only on the formation of stable peptide contacts, and APLs induce biochemical activity which is inhibitory over the agonist-delivered signals. Thus, the TCR may scan MHC molecules using a "lock and key" type of binding with its CDR1 and CDR2 loops, followed by an induced fit of its CDR3 loops over the peptide. 9 X-ray studies have shown that the TCR from human autoimmune disease binds to the peptide-HLA-DR2b complex with an off-center mechanism, which positions the CDR3 loops of the TCR over residues His 88 and Phe 89 of the N-terminus of the MBP 85-98 epitope. 10 It is one of the best characterized TCRs from a human autoimmune disease, and this aberrant binding mode provides a possible explanation for the fact that in MS autoreactive T-cells escape deletion in the thymus and attack self-myelin. Similarly, the trimolecular complex of TCRpeptide-HLA-DR2a 11 reveals that the TCR primarily recognizes the N-terminal portion of MBP peptide too.
A promising strategy in the treatment of MS has been the rational design of APLs, which inactivate autoreactive specific T-cells. These APLs could bind with high affinity with MHC and compete for recognition of self-antigens at the antigen presentation, without activating disease-causing T-cells. Indeed 12 The use of linear peptides in therapeutic protocols, though, is limited because of their proteolytic degradation.
A new strategy is to synthesize a more hydrolytically stable molecule, e.g., a cyclic peptide or a peptidomimetic that retains the desired biological activity. In our previous studies based on the immunodominant human MBP [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] , identify common features that comprise a structural motif, and hence derive conclusions relevant to the physicochemical and structural properties required for biological activity. A detailed conformational analysis of these potent cyclic agonist and antagonist peptide analogues could lead to rational designed peptidomimetics or non-peptide mimetics.
Within this scope, the following study focuses on the conformational analysis of the cyclic APLs. Experimental 2D NMR spectroscopic methods and restrained molecular dynamics simulation have been applied in order to obtain the mean structures in solution. The obtained results show that the two antagonist cyclic APLs form a bend in the middle segment of their sequence, leading to structures that are more compact, with a smaller solvent accessible area. Thus, they do not occlude weak interactions with an approaching TCR and can cause EAE antagonism. In contrast, cyclo(87-99) MBP 87-99 is more compact in the NH terminus of the molecule but presents an overall larger solvent accessible area.
Results and Discussion
A. Proton Assignment. TOCSY maps were first analyzed to assign the individual spin patterns of amino acids through scalar connectivities (Figure 1) . Sequential, medium, and long range connectivities were identified from NOESY maps acquired with τ m ) 300 ms. Chemical shift for the three peptides are reported in Tables S1-S3 in Despite the structural similarity between the three peptides and their cyclic nature, a superimposition of the backbone segment for the three cyclic conformers reveals significant differences in backbone conformation ( Figures 3A and 4) . To quantify the relative change of the position of the imidazole His 88 with respect to the phenyl rings Phe 89 (primary TCR contacts) and Phe 90 (primary MHC contact), we measured the sides of the triangles formed by the centroids of the rings ( Figure  5 [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] in Lewis rats. The structural effect of cyclization to the linear analogues was sought in order to explain the observed biologic activity. The ability of a peptide-MHC complex to activate a T-cell generally correlates with the strength and duration of TCR binding. 9 The high affinity of TCR for the pMHC and long half-lives of binding have been associated with agonist action, whereas low affinity of TCR for the pMHC with weak interactions formed and decreased half-lives of binding characterize TCR antagonism.
MS is associated with MHC II molecules (in humans referred to as Human Leukocyte Antigens, HLA). Hahn et al. 10 have reported the crystal structure (PDB code 1ymm) of the trimolecular complex of MBP 85-98 , HLA-DRB1*1501, and a TCR isolated from a patient with relapsing-remitting MS. 11, 12 This TCR represents one of the best-characterized TCRs from a human autoimmune disease, and it presents a topology notably different from that of antimicrobial ones. [13] [14] [15] The TCR contacts only the N-terminal region of the peptide and specifically residues at positions P2 His 88 and P3 Phe 89 . The natural ligand was isolated from the complex, and its conformation was used as a basis for comparison with cyclic MBP analogues.
When superimposing the sequence 88-92, the C R rmsd is 2.26 Å. Phe 90 binds in a large hydrophobic groove of HLADR2b in the X-ray structure. According to structure comparison of the NMR structure ( Figure 4B ), the phenyl ring is orientated toward the same space with the corresponding residue side chain of the linear peptide. Both TCR contacts, though, lie in a different region in space.
In order to compare the structure of the linear peptide as reported in the crystal model with the structure of the cyclic MBP derivatives, docking simulations were carried out on the cyclo(87-99) MBP 87-99 peptide (the cyclic peptide with the native sequence) with MHC. Hahn et al. have demonstrated that (i) TCR CDR3 loops create a dome-shaped cavity, large enough to accommodate both an MHC residue DR 81 His (CDR3a loop) and a peptide side chain His 88 (both CDR3a and CDR3 loop) and (ii) Phe 89 lies between the CDR3 loop and a hydrophobic region of the DR molecule. Our data for the cyclic counterpart reveal that the amino residue Pro 97 is posed in such a way that it occupies the same region in space as His 88 of the linear peptide, thus fulfilling the demands of the receptor for a bulky and hydrophobic substrate group at this cavity ( Figure  6 ). Moreover, the Phe 89 aromatic ring in the cyclo(87-99) MBP 87-99 orients toward the cavity formed by the Phe 22 , Phe 24 , and Phe 54 residues of the MHC in a remarkably similar way with the side chain of the same phenylalanine residue of the linear peptide which is accommodated in this hydrophobic cavity, according to the X-ray structure.
Smith et al. report that a large hydrophobic P4 pocket, which is occupied by Phe 90 of the linear MBP 85-98 peptide, makes an important contribution to the binding of the MBP peptide to HLA-DR2. This hydrophobic pocket is comprised of DRb79 Ala, b26 Phe, and b78 Tyr residues ( Figure 6 ). Docking simulations display that the P4 pocket is occupied by His 88 of the cyclo(87-99) MBP 87-99 model and the binding of an aromatic substrate amino acid for this cage is conserved. So His 88 , which has been inserted into this cage and replaces Phe 90 in space, exhibits stabilization through hydrophobic and Van der Waals interactions. Furthermore, it is observed that Phe 90 of the cyclo(87-99) MBP 87-99 peptide is solvent exposed (Figure 6 ). The cyclic APL has a very bulky conformation, and the overall topology is such that the TCR probably cannot approach, either with the diagonal mode suggested by the X-ray structure or with a centered approach over the peptide-HLA complex. Overall, it is clearly indicated that the conformational features of the MBP cyclic peptides as determined by NMR studies in DMSO solution are of great importance. These structurally constrained cyclic MBP analogues, according to docking simulation studies, could retain their characteristics for efficient binding to MHC receptor. On the other hand, being rather bulky compared to their parent linear peptides, they could adjust the interaction interface between MHC and TCR receptors.
E 17 , derived after comparison with the X-ray structure. These linear conformations were superimposed with their cyclic counterparts, as shown in Figure 4C The amino acid His 88 is shifted upward in both cyclic APLs, as a result of the cyclic backbone. The overall topology of both cyclic antagonist APLs is such that again the TCR cannot approach with the diagonal mode suggested by the X-ray structure. According to the rigid docking simulation, the cyclic bulky peptide is accommodated by MHC. A more conventional mode of binding of the TCR to the APL-HLA complex, i.e., centered over the peptide-HLA surface, would result in extensive contacts with both the MHC and MBP 87-99 analogues. Whether these contacts would result in an optimal fit, inducing in turn immune response with sufficient modification of the inflammatory cytokine environment providing protection against EAE, is strongly dependent on the conformational freedom and on restriction of the cyclic peptides. Such properties could be fine-tuned through structure-based engineering of MBP 87-99 sequence according to the acquired NMR structural information.
F. Proposal of a Pharmacophore Model. The NMR analysis identified structural data could lead to the establishment of a pharmacophore model for APLs presenting EAE antagonism. MOE 2006.08 25 was used for the generation of the pharmacophore model.
An essential characteristic for EAE antagonism is the formation of weak interactions between the bimolecular complex APL-MHC with the T-cell receptor. Structural data from the analysis of cyclo(87-99) MBP [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] suggest that the lack of bioactivity might be due to the overall bulky orientation of the APL over the MHC molecule, which prevents any subsequent binding of the TCR. Therefore, the first feature in the proposed pharmacophore model is the exclusion volume V1 (Figure 7 ) dictated by the space occupied by cyclo(87-99) MBP 87-99 after superimposition onto the other two cyclic antagonist APLs ( Figure 5 ). The radius of the sphere is 2.8 Å. The second feature F1 is located in the region of the phenyl ring of Phe 90 . The center of the sphere in this case lies on the virtual line connecting the centroids of the ring in the conformations of the two antagonistic APLs, while the radius is 1.9 Å, creating a volume big enough to accommodate a hydrophobic and aromatic ring. The same procedure has been followed for the third feature F2, for which the center is placed on the virtual line connecting the centroids of the phenyl ring of The last feature in the pharmacophore model, F3, was once more chosen to be generated where the imidazole ring of His 88 lies in the two APLs. The radius of the sphere is once again 1.9 Å, and the desired characteristic is occupation by an aromatic group. The pharmacophore model defined in this study contains information regarding MHC (Phe 90 ) and TCR anchors (His 88 , Phe 89 ) as well as the overall volume of the target molecules that should not occlude weak interactions with an approaching TCR and therefore may suppress EAE antagonism.
Concluding Remarks
We have determined the conformational properties of MBP peptide epitopes modified through engineering their sequence and evaluated local structural variation due to these modifications. In this way, we aim to correlate observed antagonistic activity with the structure of these restricted cyclic analogues using NMR techniques. High-resolution 3D models of synthetic MBP peptides reveal the conformational differences and similarities between linear and cyclic APLS. In combination with the known effect on their bioactivity, this could lead to the exploration of the molecular basis of EAE antagonism and the rational design of non-peptide mimetics.
NMR shows that among the three peptides the proximity of residues in positions 91 and 97 is favorable only in cyclo(87-99) [ [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] . This conformational characteristic is responsible for the more compact conformations of the antagonist APLs, which in turn possibly allows the TCR to approach, form weak interactions with the pMHC, and induce biochemical activity which is inhibitory over the agonist-delivered signals.
The design and synthesis of cyclic peptide analogues is the most important step in the rational design of peptidomimetics or non-peptide mimetics. The conformational flexibility of a cyclic analogue is restricted, and the orientation of side chain groups important for binding could lead to the design of nonpeptide analogues. In this paper, based on the conformations of the studied cyclic analogues obtained from the NMR analysis, we proposed a pharmacophore model, which will be the first step towards the design and synthesis of organic molecules using rigid templates. [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] peptide analogues were synthesized in the solid phase by Fmoc/tBu methodology using 2-chlorotrityl chloride (CLTR-Cl) resin and N a -Fmoc (9-fluorenylmethyloxycarboxyl)-protected amino acids as previously described. 7, 8 A cyclic conformation is imposed through the condensation reaction, resulting in the formation of an amide bond through the N-terminal Val 87 and C-terminal Pro 99 amino acids. The cyclization was achieved using O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU), 1-hydroxy-7-azabenzotriazole (HOAt), and 2,4,6-collidine, allowing fast reaction and high-yield final cyclic products (yield 95-98%). The purification and identification of final cyclic peptides were assessed using semipreparative reversed phase high-performance liquid chromatography (RP-HPLC) and electron spray ionization (ESI) mass spectroscopy (MS), respectively. Scheme 1 shows the primary structure of the cyclic analogues. After purification, the synthesized peptides showed a purity of 95%. Dimethylsulfoxide DMSO-d 6 (euroiso-top, C.E. Saclay, France) was used as the deuterated solvent in NMR experiments, 26 and the peptides were dissolved to a final concentration of 2-2.5 mM in order to record 1D and 2D NMR spectra. The NMR studies have been performed in DMSO in conjunction with previous studies of other MBP peptide analogues, mimicking a prototypical amphiphilic environment.
Experimental Methods
B. NMR Spectroscopy. Data were acquired at 298 K on a Bruker Avance 600 and 700 MHz spectrometers. 1 H 1D NMR spectra were recorded using a spectral width of 12-17 ppm with or without presaturation of the H 2 O signal. 1 H-1 H 2D TOCSY 27, 28 (Figure 1 ) spectra were recorded using the MLEV-17 spin lock sequence and τ m ) 80 ms, and 1 H-13 C HSQC 29 with 200.791 ppm spectral width in F1. 1 H-1 H TPPI NOESY 30,31 spectra were acquired using mixing time τ m ) 300 ms, applying water suppression during the relaxation delay and mixing time. All 2D spectra were acquired with 10.014 ppm spectral width, consisting of 2K data points in the F2 dimension, 16-32 transients, and 512-1024 complex increments in the F1 dimension. Raw data were multiplied in both dimensions by a pure cosine-squared bell window function and Fouriertransformed to obtain 2048 × 2048 real data points. A polynomial baseline correction was applied in both directions. For data processing and spectral analysis, the standard Bruker software (XWinNMR 3.5) and XEASY program 32 33 Sequential constraints, number, and range of NOEs and chemical shift differences ({(∆δ HR ) 2 + (∆δ HΝ ) 2 } 1/2 ) are illustrated in Figure 2 and Figure S1 in the Supporting Information.
D. Structure Calculations and Refinement. The NOE-derived structural information extracted from the analysis of NOESY spectra was acquired in DMSO-d 6 solutions under identical experimental conditions for all three peptides and was introduced to DYANA 34, 35 software for structure calculation. The family ensemble of 20 best DYANA models for all three peptides (out of 400 calculated) in terms of target function (<0.4 Å 2 ) and NOE violations (<0.2 Å) was submitted to energy minimization through REM (AMBER 5.0 36 , SANDER 37 program). A force constant of 133.76 kJ mol -1 Å 2 is applied for the distance constraints. MBP peptide models are illustrated in Figure 3 (figures are generated with MOLMOL 38 ). Structural calculations have been performed on IBM RISC6000 and xw4100/xw4200 HP Linux workstations. The 20 model ensemble and the mean structures of (87-99) MBP 87-99 , analogues are illustrated at Figure 3 .
E. Structure Preparation and Docking Simulation of the Peptides. The crystal structure coordinates of MHC were obtained from RCSB: PDB code 1ymm. All hetero atoms were removed. The program AutoDock 3.05 39 was used for all docking calculations, and AutoDockTools was used for visual inspection of the docking results. MHC and the cyclo(87-99) MBP 87-99 peptide were treated with the united-atom approximation by merging all nonpolar hydrogens. Kollman partial charges were assigned to all protein atoms. The grid maps were centered on the ligand's binding site, with 126 × 106 × 126 grid-points of 0.3 Å spacing. The Lamarckian genetic algorithm was employed with the parameters: a population size of 150 individuals, a maximum number of 1.5 × 10 6 energy evaluations, and a maximum number of 27 000 generations, an elitism value of 1, a mutation rate of 0.02, and a crossover rate of 0.80. 39 For all the calculations, 100 docking rounds were performed with step sizes of 0.2 Å for translations and 5°for orientations and torsions. Docked conformations were clustered with 0.5 Å tolerance for the root-mean-square positional deviation. The protein-peptide complexes were visually inspected with AutoDockTools.
F. Docking Validation. The docking simulation treating the MBP 85-99 peptide as a rigid molecule has been applied in order to explore whether the NMR-derived models of the cyclic MBP 87-99 peptides retain the structure and physicochemical features that drive their binding to MHC and TCR receptors. In order to validate this approach, rigid docking simulations have also been applied for the complex of linear MBP 85-98 with MHC, for which the X-ray structure is available. Analysis of the simulation data and interatomic distances reveals that the placement of the linear MBP [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] peptide is identical to that determined experimentally through X-ray crystallography ( Figure S2 , Supporting Information).
